Related to Scientists Find AEG-1 Expression Correlates with Response to Erlotinib Therapy

• Lab21, IntegraGen Aim to SPARQ New Cancer Diagnostic
  
• Life Tech Gains Rights to Harvard’s Stem Cell Assays
  
• BioReliance Wins Rights to Agilent’s Big Blue Colonies and Cell Lines
  
• Lonza and Hyglos Reach Agreement Settling Patent Dispute
  
• NanoString Nabs License to Liver Cancer Gene Signature
  
• Sorrento, Igdrasol Secure Exclusive E.U. Distribution Rights to Cancer Drug
  
• Pharma Touting Phase II/III Wins in Run-Up to ASCO
  
• DxS to Provide a Companion Diagnostic for AstraZeneca’s NSCLC Drug
  
• Scientists Pinpoint 93-Gene Signature that Predicts Non-Small-Cell Lung Cancer Prognosis
  
• Investigators Link Age- and Gender-Specific Gene Profiles in NSCLC to Recurrence-Free Survival
  
• Clovis Signs On to Advance Avila’s Preclinical EGFR Mutant-Selective Inhibitor Program
  
• China Medical Gets Home Country Clearance for EGFR Lung Cancer Assay
  
• Roche Sublicenses EGFR IP from Genzyme to Develop Tarceva Companion Diagnostic
  
• Phase III Shows Tarceva Extends PFS in NSCLC with EGFR-Activating Mutations
  
• EC Clears Roche’s Tarceva as Monotherapy Against Metastatic NSCLC with EGFR Mutations
  
• Life Technologies to Develop Companion Diagnostic for GSK’s Cancer Immunotherapy
  
• Qiagen Signs Two Biomarker Deals and Confirms Japanese Okay for EGFR Companion Dx
  
• Boehringer Ingelheim’s Afatinib Extends PFS in EGFR Mutation-Positive NSCLC
  
• Cancer Drugs Reverse Memory Loss in Alzheimer’s Disease
  
• FDA Approves Roche EGFR Mutation CDx for NSCLC